Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

Immunotherapy

Volumn 5, Issue 7, 2013, Pages 695-697

  Tanaka, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

humanized anti IL 6 receptor antibody; IL 6; regulatory T cell; Th17 cell; tocilizumab; Treg

Indexed keywords

INTERLEUKIN 6; TOCILIZUMAB;

ARTICLE; CD4+ T LYMPHOCYTE; DRUG EFFICACY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; RECEPTORS, INTERLEUKIN-6; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84880084417     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.47     Document Type: Article

References (15)

1. Tanaka T, Ogata A, Narazaki M. Tocilizumab: an updated review of its use in the treatment of rheumatoid arthritis and its application for other immune-mediated diseases. Clin. Med. Insights Ther. 5, 33-52 (2013)
2. Mclnnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J.Med. 365, 2205-2219 (2011)
3. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 52, 199-219 (2012)
4. Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int. J.Biol. Sci. 8, 1227-1236 (2012)
5. Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012)
6. Samson M, Audia S, Janikashvili N etal. Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 64, 2499-2503 (2012)
7. Carbone G, Wilson A, Diehl SA etal. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int. J.Biol. Sci. 9, 279-288 (2013)
8. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur. J.Immunol. 40, 1830-1835 (2010)
9. Roll P, Muhammad K, Schumann M etal. Invivo effect of the anti-interleukin-6 receptor inhibitor tocilizumab on the B-cell compartment. Arthritis Rheum. 63, 1255-1264 (2011)
10. Muhammad K, Roll P, Seibold T etal. Impact of IL-6 receptor inhibition on human memory B cells invivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann. Rheum. Dis. 70, 1507-1510 (2011)
11. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod. Rheumatol. doi:10.1007/s10165-012-0715-9 (2012) (Epub ahead of print)
12. Kieseier BC, Stuve O, Dehmel T etal. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. Arch. Neurol. 24, 1-4 (2012)
13. Ayzenberg I, Kleiter I, Schroder A etal. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 70, 394-397 (2013)
14. Chihara N, Aranami T, Sato W etal. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc. Natl Acad. Sci. USA 108, 3701-3706 (2011)
15. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 33, 571-577 (2012)